This approach, tested in a preclinical model, demonstrated the administration of intranasal polyinosine-polycytidylic (polyI:C) in conjunction with an influenza subunit vaccine, enhanced antigen-specific IgA responses [48]. This evidence concerns the gene CD79A and influenza.